BCL2 and acute myeloid leukemia: Importantly, venetoclax was shown to induce apoptosis in AML cells in a Bcl-2-dependent mechanism (Fig. 2b).83 These preclinical studies demonstrated that venetoclax was an effective orally available therapy against several AML cell lines and primary patient samples, including AML progenitor cells, and in mouse xenograft models.